Psoriasis and Inflammation

Psoriasis is one of the most common chronic skin conditions in Canada.  It has a very significant impact on patients’ quality of life.  In addition to the skin manifestations, patients may also have associated conditions like psoriatic arthritis and depression. There are different types of psoriasis, and the most common one is called plaque psoriasis.

Classically, plaque psoriasis presents itself as areas of red and inflamed skin, usually covered with thick and white or silver-colored scales.  The skin can be very itchy and/or painful. In patients with darker skin tones, the affected skin can look purple, dark gray, or brown.

Have you ever wondered how normal skin transforms into inflamed skin in psoriasis? Do you want to know how available treatments help to treat psoriasis? We will walk you through the process step-by-step and help you understand the terms used by your dermatologist.


At the end of this article, you will be able to:

  1. Understand the inflammatory and autoimmune nature of psoriasis
  2. Learn the most common key immune cells and inflammatory molecules important in psoriasis
  3. Know the differences between the targets of a group of relatively newer drugs called biologics
  4. Become familiar with other factors that may contribute to psoriasis


Psoriasis is well recognized as a chronic inflammatory condition. The red appearance of psoriasis reflects underlying sustained inflammation of the disease. It then leads to uncontrolled rapid overgrowth of skin cells (called keratinocytes), which are seen as thick scales on top of the red skin.

Fig 1 normal skin vs psoriasis Final EN

The ultimate cause of the inflammation is a malfunction of the immune system – more specifically, disturbances in the innate and adaptive immune responses of the skin.

How Does the Immune System Work?

There are two parts to the immune system: the innate system (innate immune response) and the adaptive immune system (adaptive immune response).

What are innate and adaptive immune responses? The innate immune response is the immunity everyone is born with, a type of general protection. It can quickly recognize and deal with threats in a nonspecific manner regardless of what they are.

On the other hand, adaptive immunity develops throughout our lives and is based on immune cells called T cells and B cells. You can consider T cells and B cells as the soldiers on the battlefield of the immune system. It takes time for the adaptive immune response to develop in the human body and the response to an “invader” will depend on what that invader is. There are three major types of T cells involved in psoriasis: T helper type 1 cells (Th1 cells), T helper type 2 cells (Th2 cells), and T helper type 17 cells (Th17 cells). You can think of each as a different type of soldier.

What Exactly is Inflammation?

Inflammation reflects an immune system that is activated or triggered. Most of the time, the activation is appropriate, such as when it is fighting foreign bacteria. But sometimes, the immune system can be activated in the absence of foreign invaders and mistakenly attacks your own body. We call this autoimmune disease. Psoriasis is one such autoimmune disease.

There are two important components of the activation of the immune system:

  1. overgrowth of immune cells, and
  2. increased inflammatory molecules (called cytokines).

If you take a small sample of the skin from patients with psoriasis and examine it under the microscope, you will see abnormally abundant immune cells, including dendritic cells, macrophages, T cells, and neutrophils, present in different layers of the skin or even in the blood vessels. At the same time, the level of cytokines are significantly elevated. If the immune cells were the soldiers, the cytokines can be considered the bullets/bombs. You can imagine the immune cells (soldiers) and cytokines (bullets/bombs) working hand in hand to contribute to the initiation of the skin inflammation in psoriasis.

Phases of Inflammation

There are two phases of the development of psoriasis: 1) the initiation phase, possibly triggered by mostly unknown factors and a few known factors (trauma to the skin, skin infection, or certain drugs); and 2) the maintenance phase with a chronic clinical progression.

Fig. 3 Psoriasis Cycle for GIF Final 2 EN

Initiation Phase: The initiation phase is based on the innate immune response. The exact first step of the inflammation in psoriasis is unclear, but we have observed that psoriasis can be triggered by some sort of “trauma” to the skin, including direct trauma to the skin (e.g., a cut, bruise, burn, or bump), skin infection by microorganisms, etc. The reason that not all people with skin trauma will develop psoriasis is that there is a genetic component playing a role, which makes some people more susceptible to developing psoriasis.

When the skin experiences the trauma, the trauma kicks off a chain reaction, involving immune cells and cytokines. First, the injured skin cells (keratinocytes) release small molecules called antimicrobial peptides (AMPs) [Step 1 in the diagram]. Then, AMPs activate one particular type of immune cell called plasmacytoid dendritic cell, which produces a cytokine called interferon-alpha (IFN-alpha) [Step 2 in the diagram]. After that step, the IFN-alpha activates another type of immune cell called myeloid dendritic cells. A bunch of dendritic cells then become activated and they will secrete two very important cytokines called tumor necrosis factor-alpha (TNF-alpha) and interleukin-23 (IL-23), [Step 3 in the diagram]. If you could stop the chain of reactions at any point, the inflammation will improve. This is the reason that TNF-alpha or IL-23, are the targets for many psoriasis drugs, as you will see later.

Maintenance (Chronic) Phase: In contrast, the maintenance (chronic) phase of the inflammation in psoriasis is based on adaptive immune system.

As mentioned in the immune response section above, there are different types of soldiers in the adaptive immune system. The most important ones here are the Th17 cells, which play a crucial role in many autoimmune diseases, including psoriasis and Crohn’s disease, a type of inflammatory bowel disease that may affect any segment of the digestive tract. The elevation of TNF-alpha and IL-23 from the initiation phase will lead to the activation of Th17 cells. How about IL-12? IL-12 activates the Th1 component of the adaptive immune system, which is less understood than Th17. Let’s go back to Th17.

With the activation of Th17 cells, two other important cytokines are released: IL-17A and IL-22 [Step 4 in the diagram]. Both IL-17A and IL-22 will activate keratinocytes. The activation of keratinocytes perpetuates the inflammation by completing the whole cycle as shown in Step 5 of the diagram. With the completion of the cycle, the active inflammation will exacerbate psoriasis in the absence of the initial triggers (for example, an initial skin trauma).

Besides dendritic cells and Th17 cells, there are also other types of immune cells that are abundant in the skin cells that are affected by psoriasis, named macrophages and neutrophils. We know they contribute to psoriatic inflammation, but their specific roles are not well understood yet.

Different Drugs Work on Different Cytokines

You may wonder why we are discussing different cytokines. The reason is that cytokines function as the targets of different medications, which work to reduce the number of cytokines that are activated. A lower level of cytokines results in less inflammation and ultimately the improvement of psoriasis.

By knowing the cytokines, you will be able to easily understand how the medication you are taking may work. Many medications for treating moderate-to-severe psoriasis are biologics, a group of medications given to a patient through infusion into the veins or injection under the skin. Each medication targets a specific cytokine, for example, infliximab is an anti-TNF-alpha drug that targets and lowers the level of TNF-alpha. There are many biologics available to patients in Canada.

Cytokine Drug

Etanercept (Enbrel)

Adalimumab (Humira)

Infliximab (Remicade)

Certolizumab (Cimzia)


Risankizumab (Skyrizi)

Guselkumab (Tremfya)

Tildrakizumab (Ilumya)

 anti-IL-12/23 Ustekinumab (Stelara)

Brodalumab (Siliq)

Ixekizumab (Taltz)

Secukinumab (Cosentyx)

anti-IL-17A/F Bimekizumab (Bimzelx)

 Table 1. Biologics and Their Drug Target in the Treatment of Psoriasis

Other Body Processes Impacted By Psoriasis

Besides inflammation, there are also a few other components that may contribute to the manifestations of psoriasis. In the blood vessels of psoriatic skin, there is an elevated level of molecules that stimulate the overgrowth of cells lining the blood vessels. Therefore, the blood vessels feeding the skin become dilated, tortuous, and leaky which cause the red color and bleeding of the skin.

Besides skin trauma mentioned earlier, certain other environmental factors seem to have a role in the onset of psoriasis or potentially exacerbate psoriasis, including bacterial and viral infection, cigarette smoking, alcohol use, emotional stress, and certain medications. The most common medications are beta-blockers for improving heart function, lithium for certain mood disorders, and antimalarial drugs.

What Is Next?

Clinicians and scientists are working hard to further understand what causes psoriasis and makes it develop. With better understanding of these underlying processes, new drugs can be developed to achieve improved health outcomes for patients and improve patients’ quality of life.


Now, you learned a lot about psoriasis. Try to answer the questions below and see how much you have learned.

Question 1. Which of the following statements about psoriasis is INCORRECT?

  1. Psoriasis is a chronic inflammatory skin condition.
  2. Psoriasis is marked by decreased level of immune cells and cytokines.
  3. Psoriasis is an autoimmune condition, like Crohn’s disease.
  4. Psoriasis could be triggered by skin trauma.

 Question 2. If you and your dermatologist decided to treat your psoriasis with a drug called etanercept which is an anti-TNF-alpha injection medication, what will the drug do?

  1. The drug aims to increase TNF-alpha level in your body to increase inflammation
  2. The drug aims to increase TNF-alpha level in your body to decrease inflammation
  3. The drug aims to decrease TNF-alpha level in your body to decrease inflammation
  4. The drug aims to decrease TNF-alpha level in your body to increase inflammation

Question 3. Which of the following factors could potentially make your psoriasis worse?

  1. Bacterial infection
  2. Cigarette smoking
  3. Alcohol consumption
  4. All of the above

Answers to the questions: B-C-D


  1. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128:1064.
  2. Boehncke WH, Wortmann S, Kaufmann R, et al. A subset of macrophages located along the basement membrane ("lining cells") is a characteristic histopathological feature of psoriasis. Am J Dermatopathol 1995; 17:139.
  3. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180:1141.
  4. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129:1339.
  5. Di Meglio P, Villanova F, Nestle FO. Cold Spring Harb Perspect Med 2014: 4:6.
  6. Glowacka E, Lewkowicz P, Rotsztejn H, Zalewska A. IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis. Adv Med Sci 2010; 55:254.
  7. Hänsel A, Günther C, Ingwersen J, et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol 2011; 127:787.
  8. Hollox EJ, Huffmeier U, Zeeuwen PL, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008; 40:23.
  9. Liang, Y.; Sarkar, M.K.; Tsoi, L.C.; Gudjonsson, J.E. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr Opin Immunol 2017: 49:1–8.
  10. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128:1207.
  11. Martini E, Wikén M, Cheuk S, et al. Dynamic Changes in Resident and Infiltrating Epidermal Dendritic Cells in Active and Resolved Psoriasis. J Invest Dermatol 2017; 137:865.
  12. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006; 27:17.
  13. Morizane S, Gallo R.L. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol 2012; 39:225–230.
  14. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of t lymphocytes and induction of th1 type cytokines. J Clin Investig 1994; 94: 202–209.
  15. Reich K, Papp KA, Matheson RT, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol 2015; 24:529.
  16. Rendon A, Schakel K. Psoriasis pathogenesis and treatment. J Mol Sci 2019; 20:1475.
  17. Szabo SK, Hammerberg C, Yoshida Y, et al. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 1998; 111:1072.
  18. Uyemura K, Yamamura M, Fivenson DF, et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101:701.
  19. van der Fits L, van der Wel LI, Laman JD, et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 2004; 122:51.
  20. van de Kerkhof PC, Lammers AM. Intraepidermal accumulation of polymorphonuclear leukocytes in chronic stable plaque psoriasis. Dermatologica 1987; 174:224.
Written by:
Dr. Harry Liu
Reviewed by:
Dr. David Adam, December 2020